[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 3 of about 3
1. Wernicke J, Pangallo B, Wang F, Murray I, Henck JW, Knadler MP, D'Souza DN, Uetrecht JP: Hepatic effects of duloxetine-I: non-clinical and clinical trial data. Curr Drug Saf; 2008 May;3(2):132-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Seven of 23,000 duloxetine- and 2/6000 placebo-treated patients met criteria for modified Hy's rule (significant elevation of both ALT and total bilirubin) but were complicated by contributing factors such as excessive alcohol consumption (n=3), gall stones, common bile duct calculus, hepatitis C, and liver adenocarcinoma (n=1 each).
  • CONCLUSIONS: Duloxetine has an effect on the liver, manifested by transient, self-limiting transaminase elevations.
  • Rare events characterized as hepatocellular injury, cholestatic injury, or mixed type of hepatic injury have been reported.
  • The pattern of liver effects was different from that in laboratory animals.
  • [MeSH-major] Adrenergic Uptake Inhibitors / adverse effects. Drug-Induced Liver Injury. Liver / drug effects. Serotonin Uptake Inhibitors / adverse effects. Thiophenes / adverse effects
  • [MeSH-minor] Alanine Transaminase / blood. Alkaline Phosphatase / blood. Animals. Aspartate Aminotransferases / blood. Bilirubin / blood. Biomarkers / blood. Clinical Trials as Topic. Consumer Product Safety. Drug Evaluation, Preclinical. Duloxetine Hydrochloride. Humans. Liver Diseases / enzymology. Risk Assessment. Risk Factors. Species Specificity

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • Hazardous Substances Data Bank. DULOXETINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Curr Drug Saf. 2009 Jan;4(1):94
  • (PMID = 18690991.001).
  • [ISSN] 2212-3911
  • [Journal-full-title] Current drug safety
  • [ISO-abbreviation] Curr Drug Saf
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] 0 / Adrenergic Uptake Inhibitors; 0 / Biomarkers; 0 / Serotonin Uptake Inhibitors; 0 / Thiophenes; 9044SC542W / Duloxetine Hydrochloride; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase; EC 3.1.3.1 / Alkaline Phosphatase; RFM9X3LJ49 / Bilirubin
  • [Number-of-references] 30
  •  go-up   go-down


2. Bombardieri E, Aliberti G, de Graaf C, Pauwels E, Crippa F: Positron emission tomography (PET) and other nuclear medicine modalities in staging gastrointestinal cancer. Semin Surg Oncol; 2001 Mar;20(2):134-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positron emission tomography (PET) and other nuclear medicine modalities in staging gastrointestinal cancer.
  • The most frequently involved sites are, in descending order, the colorectum, stomach, pancreas, liver, bile duct, and esophagus.
  • The most common tumor type is adenocarcinoma.
  • These concepts are relevant because nuclear medicine imaging is based on visualization by means of a particular uptake of radiolabelled tracers in cancer cells that concentrate the radioactive signal.
  • Different radiopharmaceuticals have been proposed for diagnostic application in oncology (such as radiolabelled monoclonal antibodies (MAbs), receptor tracers, and positron-emitting radiopharmaceuticals), and they are currently used as tracers for tumor detection with different modalities and techniques.
  • This work is not intended to be a comprehensive review of all the extensive experience and possibilities of nuclear medicine for the diagnosis of GI tumors; rather, it aims to summarize the current status of the most important approaches and their main indications in staging GI cancers.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Wiley-Liss, Inc.
  • (PMID = 11398207.001).
  • [ISSN] 8756-0437
  • [Journal-full-title] Seminars in surgical oncology
  • [ISO-abbreviation] Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Radiopharmaceuticals; 0 / Receptors, Somatostatin; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 125
  •  go-up   go-down


Advertisement
3. Berr F, Wiedmann M, Tannapfel A, Halm U, Kohlhaw KR, Schmidt F, Wittekind C, Hauss J, Mössner J: Photodynamic therapy for advanced bile duct cancer: evidence for improved palliation and extended survival. Hepatology; 2000 Feb;31(2):291-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy for advanced bile duct cancer: evidence for improved palliation and extended survival.
  • Median survival time of nonresectable hilar bile duct cancer is only 4 to 6 months owing to tumor spread in the biliary tree, refractory cholestasis, and sepsis or liver failure.
  • We explored whether local photodynamic therapy of nonresectable bile duct cancer could improve survival.
  • Twenty-three consecutive patients (8 women, 15 men; 67 +/- 14 years) with nonresectable bile duct cancer (Bismuth type III n = 2, type IV n = 21) were treated with photodynamic therapy and biliary endoprosthesis.
  • Photofrin (QLT Pharmaceuticals, Vancouver, Canada) (2 mg/kg body weight intravenously) was photoactivated after 1 to 4 days with laser light (630 nm; 242 J/cm(2)) via endoscopic retrograde access.
  • All patients, except 1 with diffuse liver metastases, improved in cholestasis, performance, and quality of life.
  • Photodynamic therapy can prevent tumor occlusion of hilar bile ducts.
  • [MeSH-major] Adenocarcinoma / drug therapy. Bile Duct Neoplasms / drug therapy. Palliative Care. Photochemotherapy

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10655248.001).
  • [ISSN] 0270-9139
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down






Advertisement